August 24, 2017 09:14 AM EDTUpdated 10:18 AM
News Briefing

Trou­bled Im­muno­Cel­lu­lar slash­es costs, jobs in re­struc­tur­ing; Ac­cel­er­at­ed Phar­ma dumps strug­gling IPO ef­fort

Shehla Shakoor

Managing Director

⇨ LA-based Im­muno­Cel­lu­lar Ther­a­peu­tics $IMUC is push­ing through a cost-cut­ting pro­gram, slash­ing staff and fa­cil­i­ties in the process. Two board mem­bers are al­so leav­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times